George Morris, chief operations officer of (), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly.
He says by nature they're detailed and complex but he hopes they'll be completed shortly and he's looking to undertake the trial early next year.
''[There's] significant interest in all the relevant areas most definitely'', Morris adds.
He also updates on developments within the rest of the portfolio including VAL 201 which is still in a phase I/II trial for patients affected by hormone- sensitive and hormone-resistant prostate cancer.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE